Milbank partners David Gindler and Errol Taylor were recognized as Intellectual Property Stars in the eighth edition of LMG Life Sciences. Presented by the research arm of Euromoney’s Legal Media Group, this guide serves as a comprehensive breakdown of life sciences industry leaders on both the firm and attorney level that specialize in corporate, regulatory, litigation and intellectual property matters.
David Gindler is a partner in the Los Angeles office of Milbank LLP and the head of the firm’s Intellectual Property Litigation and Licensing Group. Mr. Gindler’s practice focuses on intellectual property litigation and licensing, with an emphasis on complex patent litigation. He is nationally recognized by Chambers USA for his expertise in life sciences matters. Mr. Gindler has achieved extraordinary trial outcomes for both plaintiffs and defendants, including a $302 million verdict for breach of a research and license agreement, as well as defeating a $217 million damages claim where liability had already been established in an earlier trial handled by a different law firm. Mr. Gindler has represented both established and emerging commercial and nonprofit organizations, including Genentech, Biogen, ZOLL Medical Corporation, CooperVision, Alnylam Pharmaceuticals, PDL BioPharma, Aon Corporation, Arizona State University and City of Hope.
Errol Taylor is a partner in the New York office of Milbank LLP and a member of the firm’s Intellectual Property Litigation and Licensing Group. Mr. Taylor represents research pharmaceutical, biotechnology and chemical companies in patent litigation, appeals and related counseling. Prior to becoming a lawyer, Mr. Taylor was a biologist who worked in pharmaceutical research. He has over 25 years of experience advising companies in complex patent issues and has been recognized as one of the world’s leading pharmaceutical litigators, including by Chambers USA, Lawdragon, and the National Law Journal. Mr. Taylor has particular expertise in cases involving generic drug approvals and the Hatch-Waxman Act. He has served as lead trial and appellate counsel in numerous multi-party, multinational cases for leading biopharmaceutical companies involving some of the world’s most prescribed medicines.
Milbank’s Intellectual Property practice provides comprehensive and sophisticated IP service. We offer a comprehensive approach to dispute resolution and problem-solving. In addition to litigation, Milbank provides pre-litigation counselling, infringement and validity opinions, transactional IP representation, patent prosecution, and assistance with alternative dispute resolution and settlement negotiations. Milbank’s IP lawyers have extensive experience in the life sciences sector, managing the intersection of pharma patent litigation and FDA and FTC issues, and negotiating numerous complex settlements in Hatch-Waxman cases.
